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Abstract
Background and Purpose—To identify novel risk factors for intracerebral hemorrhagic stroke
(ICH)
Methods—Risk factors were assessed at baseline in a pooled cohort of the Atherosclerosis Risk in
Communities Study (ARIC) and the Cardiovascular Health Study (CHS), involving 21,680 adults,
aged 45 or over. Over 263,489 person-years of follow-up, we identified 135 incident ICH events.
Results—In multivariable models, for each standard deviation higher baseline level of fibrinogen
the relative rate of incident ICH increased 35% (95% CI 17%−55%). Fibrinogen was more strongly
related to ICH in ARIC than in CHS. In multivariable models those with von Willebrand factor (vWF)
levels above the median were 1.72 (95% CI 0.97−3.03) times more likely to have an incident ICH
as those below the median. Factor VIII was significantly positively related to ICH in ARIC (relative
rate per standard deviation of 1.31, 95% CI 1.07−1.62), but not in CHS. There was no relation in
multivariable models between Lp(a), factor VII, white blood cell count, or C-reactive protein and
ICH.
Conclusions—Greater plasma fibrinogen, and to some degree vWF, were associated with
increased rates of ICH in these prospective studies, while factor VIII was related to ICH in younger
ARIC study participants only.
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Stroke is the third leading cause of death in the United States.1 Intracerebral hemorrhage (ICH)
is the most common cause of hemorrhagic stroke and has a higher case fatality than ischemic
stroke. Currently, few effective evidence-based treatments exist for ICH.2-4
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ICH has been strongly linked to age, African-American ethnicity, and hypertension status;5
however, other risk factors demonstrate less consistent associations. Only a few reports have
examined ICH and hemostatic and other novel risk factors for vascular disease, despite strong
biological plausibility.
Intracerebral hemorrhages are frequently seen in populations with bleeding disorders, in
particular hemophiliacs,6 suggesting a potential link between hemostatic variables and ICH in
the general population. Inflammation is increasingly recognized as an important contributor to
the etiology of many vascular diseases;7 however, it is unknown if inflammation is associated
with ICH.
We studied the associations of fibrinogen, von Willebrand factor (vWF), factor VII, factor
VIII, white blood cell count, and C-reactive protein with ICH incidence in a pooled study of
two prospective population-based cohorts, the Atherosclerosis Risk in Communities Study and
the Cardiovascular Health Study.
Methods
The ARIC study cohort consists of a population sample of 15,792 individuals from four
communities: the northwestern suburbs of Minneapolis, Minnesota; Jackson, Mississippi;
Forsyth County, and North Carolina; Washington County, Maryland. The Jackson sample
comprised African-American residents only. ARIC participants were 45−64 years old at
baseline when recruited between 1987−1989.8
CHS is a randomly selected population-based cohort study from four communities: Pittsburgh,
Pennsylvania; Forsyth County, North Carolina; Sacramento County, California; and
Washington County, Maryland. CHS recruited 5201 participants from 1989−1990, and
subsequently added 687 African-Americans from 1992−1993. Potential participants ≥65 years
old were randomly sampled from the Health Care Financing Administration (HCFA or
Medicare) eligibility lists.9 These studies received approval from relevant human subjects
review boards and all participants gave voluntary consent.
ARIC and CHS measured many baseline risk factors, as detailed elsewhere.10-13 Both studies
employed comparable methods to assess most risk factors allowing for the pooling of the
studies.
CHS phlebotomy methods and quality assurance have been published in detail and were
adapted from ARIC laboratory methods.9,14 Fasting plasma total cholesterol and triglycerides
were measured enzymatically according to Centers for Disease Control and Prevention
guidelines. Low-density lipoprotein (LDL) was calculated using the Friedwald equation; high
density lipoprotein (HDL) was measured following precipitation of other lipids.
Blood was drawn from ARIC participants after a 12 hour fast. Details on blood collection and
hemostatic analytes have been published.15 Blood was drawn into vacuum tubes with sodium
citrate (hemostatic factors), silicon (insulin and chemistries), and EDTA (lipids and cell
counts). Blood was stored at 4°C and white blood cell count determined by automated particle
counters (model dependent on ARIC site) within 24 hours of blood draw. Leukocyte count
replicate measurements demonstrated reliability coefficients of between 0.96 and 1.00.
Additional aliquots were centrifuged at 4°C at 3000 g for 10 minutes and stored at −70°C for
analysis of other plasma and serum measures at the central ARIC laboratory at the University
of Texas Health Science Center in Houston. Samples were shipped within one week of being
drawn, and analysis was conducted within 2 weeks of arrival. Fibrinogen was measured by
thrombin-time titration with reagents from General Diagnostics (Fibriquick, Organon-
Technika Co, Morris Plains, NJ). Factor VII activity was measured by the clotting rate of human
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factor VII deficient plasma; factor VIII activity was assessed with VIII deficient plasma.
Materials for factor VII and VIII measurement came from George King Biomedical Inc,
Overland Park, Kansas. Factor VII and VIII levels were expressed as a percentage of clotting
activity determined from a calibration curve constructed from freeze-dried reference plasma
from Pacific Hemostasis (Curtin Matheson, Houston, Texas). von Willebrand factor was
measured using enzyme-linked immunosorbent assay (ELISA) kits (American Bioproducts
Co, Parsipanny, NJ). ARIC hemostasis variables were measured repeatedly in certain
individuals over weeks to assess reliability. The reliability coefficient was 0.68 for von
Willebrand factor, 0.78 for factor VII, 0.86 for factor VIII, and 0.72 for fibrinogen.15,16 Intra-
assay and interassay coefficients of variation of all hemostatic assays were below 5%.17 Lp
(a) was measured in plasma samples using a double-antibody ELISA technique for the apo(a)
protein component of Lp(a).
CHS measured white blood cell count at each field center using automated particle counting
instruments. Lp(a) was measured using a highly specific monoclonal ELISA that reacts to the
isoforms of Lp(a) (Genentech). Results are reported as the protein component, excluding the
cholesterol and phospholipid components.18 Fibrinogen was measured using the Clauss
method. As with ARIC, CHS measures of factor VII and VIII were coagulant activity measures.
Factor VII was measured using Coag-A-Mate X2 (Organon Teknika) with deficient plasma
from Baxter-Dade and Thromborel S (Behring Diagnostics, Marburg, Germany) with a
coefficient of variation of 5.3%. Factor VIII was measured using Coag-A-Mate, factor VIII
deficient plasma, and partial thromboplastin reagent from Organon Teknika with a coefficient
of variation of 9.7%.19,20 CRP was measured in stored plasma samples using a high sensitivity
immunoassay with an inter-assay coefficient of variation of 6.3%.21 CRP was not measured
in ARIC.
ARIC outcomes were gathered through annual phone interviews, follow-up examinations,
community hospital surveillance, and reported deaths. A reported hospitalization led to
screening, and if suitable, to medical record abstraction. Potential acute stroke events were
abstracted if the discharge diagnosis included a cerebrovascular disease code (International
Classification of Diseases, 9th revision, code 430 to 438), if a cerebrovascular procedure was
mentioned in the summary, or if the computed tomography or magnetic resonance report
showed evidence of acute cerebrovascular disease.12 In ARIC, hospitalized strokes and out of
hospital stroke deaths are included, but not nonfatal, non-hospitalized strokes.
CHS surveillance and cerebrovascular event ascertainment have been described in detail.22,
23 CHS participants were called every six months and questioned about interim medical events.
Self-or proxy-reported potential stroke events were explored and medical records abstracted
for verification. CHS also searched HCFA Medicare Utilization files for stroke ICD-9 codes
(430−438) and upon event identification abstracted records for verification. CHS searched
reported deaths for CHS participants. In CHS, fatal and non-fatal hospitalized and non-
hospitalized strokes were ascertained.
ARIC adapted the National Survey of Stroke criteria for its stroke definition.24 These criteria
require cerebrovascular events to have evidence of sudden or rapid onset of neurological
symptoms that last for > 24 hours or lead to death, and the event had no other apparent cause
such as trauma, tumor, infection, or anti-coagulation therapy. A definite ICH must have met
one of the following criteria: (A) CT or MRI showing intracerebral hematoma; (B)
Demonstration at autopsy or surgery of ICH; or (C) (1) at least one major or two minor
neurological deficits and (2) bloody spinal fluid on lumbar puncture and (3) cerebral
angiography demonstrates an avascular mass effect and no evidence of aneurysm or
arteriovenous malformation and (4) no CT or MRI. A probable ICH met criteria C1, C2, C4
with a decreased level of consciousness or coma lasting 24 hours or until the participant died.
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In ARIC, 98% of strokes underwent a CT or MRI. In ARIC, stroke criteria were computer
automated, and reviewed by a physician blinded to the automated results. A second physician
adjudicated disagreements between the computer and initial physician.
CHS adopted stroke criteria similar to the Systolic Hypertension in the Elderly Program
(SHEP).11,25 Potential stroke events in CHS were referred to a Cerebrovascular Adjudication
Committee. The committee consisted of a neurologist (or internist) representing the
coordinating center, a neurologist from each site, and a neuroradiologist. A suspected event
was classified as a stroke if there was a rapid onset neurological deficit (or subarachnoid
hemorrhage) lasting > 24 hours or until death. A suspected hemorrhagic stroke was classified
as an ICH if (A) there was CT or MRI evidence of ICH, or (B) bloody cerebrospinal fluid on
lumbar puncture with a focal deficit or (C) autopsy or surgical evidence indicated ICH. The
event could not be attributed to trauma, tumor, or infection, but in contrast to ARIC a
hemorrhagic cerebrovascular event while on anti-coagulation therapy did not preclude an ICH
classification in CHS. Only 7 participants with an ICH in CHS were potentially taking anti-
coagulation medication. Their exclusion had little impact on results, as would be expected from
the small numbers and since anti-coagulation was only weakly correlated with exposures of
interest. The CHS Committee has assessed its reliability by blindly reviewing 30 stroke cases.
They reported a kappa of 0.86 for stroke versus no stroke, and a kappa of 1.0 for stroke subtype
(ICH vs SAH vs ischemic). In CHS 86% of stroke events had brain imaging as part of their
event work-up. In both studies suspected ICH events describing anti-coagulation therapy as a
major contributing cause were not classified as ICH.
The pooled cohort had 21,680 participants at baseline with follow-up through June 30, 2002
for CHS and December 31, 2002 for ARIC. Participants reporting a history of stroke at baseline
(n=582) or were not African-American or white (n=87) were excluded. Participants who did
not fast 8 hours prior to baseline blood draws were excluded from analysis involving
triglycerides (n=560). The outcome of interest was definite or probable incident ICH. In the
rare cases of repeat ICH the analysis was limited to initial ICH.
The association of baseline risk factors with incident ICH was assessed. Relative rates and
incident rate estimates were calculated using Poisson regression as implemented in SAS 8.2
(SAS Institute, North Carolina). Two-way multiplicative interactions between all risk factors
and study (ARIC, CHS), age, race (whites vs blacks), and hypertension (continuous systolic
pressure and hypertension categories) were examined. Power was 80% to detect a relative risk
of 1.6 for a dichotomous exposure with 30% exposed. All variables were tested in crude and
age-adjusted models. Variables were tested in a Poisson model with ICH as the outcome and
adjusted by potential confounders that demonstrated an independent association with ICH in
this combined cohort in a previous report: age, race, blood pressure, LDL-C, and triglycerides.
Variables that were significant at the alpha=0.05 level after confounder adjustment were
considered associated with ICH.
Results
Table 1 shows selected baseline characteristics of ARIC and CHS. Because of the large sample
size and difference in age between cohorts, most baseline variables differed significantly
between the studies.
Over 263,489 person-years 135 incident ICH events occurred (61 in ARIC, 74 in CHS). The
median follow-up time was 13.5 years for participants free of ICH, and median time to event
was 8.0 years for participants experiencing an ICH. Table 2 illustrates the crude and age-
adjusted relative rates of ICH in categories of novel risk factors. Fibrinogen, Lp(a), and vWF
(ARIC only) had statistically significant positive associations (p<0.05) with incident ICH prior
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to adjustment for potential confounders or testing for interactions. CRP (CHS only), factor VII,
factor VIII, and WBC count were not significantly associated with incident ICH (p>0.05).
vWF was moderately positively associated with ICH with more than two-fold greater risk for
those above the median of 109% compared to those below the median (Table 2). After
adjustment for age, hypertension, and systolic blood pressure the relation between vWF and
ICH was slightly attenuated and of borderline statistical significance, with a relative rate of
1.72 (95% CI 0.97−3.03) for those above the median versus those below the median.
Adjustment for other potential confounders did not substantially alter this association.
As shown in Table 2, the association of Lp(a) with ICH was of borderline statistical significance
in CHS (p-value for trend across quartiles = 0.10) and significant in ARIC (p-value for trend
= 0.02). Adjustment for race fully attenuated this association between Lp(a) and ICH in both
studies. In both studies adjustment for other potential confounders did not meaningfully alter
the lack of association between Lp(a) and ICH after adjustment for race.
Fibrinogen was positively related to incident ICH prior to adjustment for covariates (Table 2).
Table 3 illustrates the relation between fibrinogen per SD (66.2 mg/dl) and incident ICH in
crude and adjusted models. After adjustment for age, systolic blood pressure, race, and lipids,
for each SD greater fibrinogen there was a 1.35-fold greater risk of ICH (95% CI 1.17−1.55).
After multivariable adjustment, participants in the highest 10% of fibrinogen were 2.43 (95%
CI 1.60−3.69) times as likely to have had an ICH as those in the lower 90%.
During analysis all variables were tested for potential interactions with age, race, systolic blood
pressure, and study (CHS, ARIC) in their relation to ICH. Both fibrinogen and factor VIII
demonstrated interactions with age. The association between fibrinogen and ICH was weaker
in the older CHS participants than the younger ARIC participants (p<0.01). In CHS the
multivariable adjusted relative rate of ICH was 1.17 for each SD greater fibrinogen (95% CI
0.94−1.47), while this was 1.53 (95% CI 1.28−1.83) in ARIC. The age/study interaction for
factor VIII with ICH was more apparent, with an adjusted relative rate for each SD higher
factor VIII of 1.31 (95% CI 1.07−1.62) in ARIC, compared to 0.85 (95% CI 0.65−1.12) in
CHS (interaction p-value <0.001).
Discussion
In this pooled population-based study of potentially novel risk factors for ICH, fibrinogen,
vWF (borderline significant), and factor VIII (ARIC) were positively associated with incident
ICH after multivariable adjustment. There was no independent relation between WBC, CRP,
factor VII, or Lp(a) and ICH.
We previously reported the traditional cardiovascular risk factors levels in ARIC and CHS and
their relation to ICH.26 Hypertension, the most important risk factor for ICH, was linearly
related to the hemostatic risk factors, WBC, and CRP. Compared to non-hypertensives,
hypertensives had mean values that were 2% higher for WBC, 4% higher for factor VII and
factor VIII, 5% higher for fibrinogen, 9% higher for vWF, and 11% higher for CRP.
Few studies have examined ICH in relation to the three hemostatic proteins most widely studied
in relation to cardiovascular risk: fibrinogen, factor VIII, and vWF. Because intracranial
bleeding is more likely in those with bleeding disorders, low levels of these hemostatic factors
in the general population could contribute to a pro-hemorrhagic state that increases the risk of
ICH. However, our results seemingly contradict this general hypothesis, as we observed
positive, not inverse associations, between these procoagulant variables and ICH. Yet, few
participants had clearly “deficient” levels of these factors, even in the lowest quartile.
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Factor VIII and vWF are highly correlated (r = 0.73 in ARIC).27 Both factors were positively
associated with ICH in ARIC after multivariable adjustment. In contrast, a Swedish nested
case-control study with an average participant age of 51 reported an inverse association
between vWF and ICH (n=39), with a multivariable adjusted odds ratio of 0.27 (95% CI 0.08
−0.90) for the highest tertile versus the lowest.28 Our study is the first to report a positive
association between factor VIII and ICH. The strong interaction between factor VIII and study
or age in relation to ICH suggests that the association is meaningful in younger, but not older,
participants.
Elevated fibrinogen, which represents inflammation and hemostatic balance, is considered pro-
thrombotic and has been linked to greater atherosclerosis, sub-clinical vascular disease, heart
disease outcomes, and ischemic stroke.29-33 Only recently has fibrinogen been associated
with hemorrhagic stroke.29,34,35 Consistent with our results, all of these studies29,34,35
reported greater fibrinogen was associated with a higher risk of ICH. It seems somewhat
paradoxical that elevated fibrinogen, if prothrombotic, would be associated with greater risk
of hemorrhagic stroke. Previous studies have suggested that higher fibrinogen is associated
with a lack of nocturnal declines in blood pressure, a trait that may increase risk of ICH.36,
37 It is also possible that fibrinogen represents a component of inflammation that is meaningful
in ICH. Yet, we found that neither C-reactive protein nor WBC, other inflammatory markers,
was associated with ICH. The fibrinogen by study interaction in association with ICH suggests
that any relation with inflammation may weaken with advancing age. While CRP was only
measured in CHS, WBC count was available in both studies and demonstrated no interactions
by study, nor did it demonstrate any relation with ICH. If the association between ICH and
fibrinogen is causal and related to inflammation, we might have expected similar associations
with WBC and ICH in this study.
Lp(a) has been linked to increasing risk of coronary heart disease, but no studies have examined
the potential association between Lp(a) and ICH. Despite the potential to exert effects through
both hemostatic and lipid pathways,38-40 Lp(a) did not demonstrate any association with ICH
after adjustment for race. Lp(a) level is strongly hereditary and differs by race.41
Despite the relatively large number of events, this study still had limited power to detect weak
associations. Despite the relative similarity in ICH classifications in CHS and ARIC,
differences in classification could have affected the results. These potential differences could
result in misclassification of the exposures or outcome that would bias the results in
unpredictable ways. Although the methods of measurement of baseline risk factors were similar
between ARIC and CHS, unidentified differences could exist. This study examined variables
measured at baseline that may have changed for participants during follow-up, resulting in
exposure misclassification. ICH stroke subtype and hemorrhage location were not assessed in
these studies preventing the examination of possible associations between ICH subtypes and
potential risk factors. Baseline ages for ARIC and CHS did not overlap, resulting in age and
study being confounded. Although study (ARIC vs. CHS) was not independently related to
ICH, there is the possibility of residual confounding or study interactions due to methodological
or population differences. This suggests particular caution in interpreting the observed
interactions of age/study with fibrinogen and factor VIII.
In summary, our study found an increased risk of ICH with a greater fibrinogen level and this
relation was somewhat stronger in younger ARIC participants. We also observed a positive
association between factor VIII and ICH in ARIC participants and some degree of association
between vWF and ICH.
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Table 1
Mean or Prevalence of Baseline Measures by Study, ARIC/CHS Cohort
Study
Baseline Measures ARIC CHS P-value
n 15,460 5,551
Age, y 54.2 72.8
Male, % 44.8 42.4 0.001
Black, % 27.1 15.8 <0.001
Hypertension, % 35.4 65.9 <0.001
Total Cholesterol, mg/dl 215.0 211.3 <0.001
Lp(a), μg/mL 101.3 53.6 Incomparable Assays
Factor VII, % 118.8 123.4 <0.001
Factor VIII, % 131.6 122.4 <0.001
Fibrinogen, mg/dl 303.6 323.8 <0.001
White blood count, cells/mm3 6,131 6,308 <0.001
von Willebrand Factor, % 118.1 Not measured
C-reactive protein, mg/dl Not measured 3.59
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Table 3
Relative Rates of Intracerebral Hemorrhagic Stroke per Standard Deviation of Greater Fibrinogen Using Different
Modeling Strategies, ARIC/CHS Cohort
Model Relative Risk (per SD
= 66.2 mg/dl)
95% Confidence Interval P-value
Fibrinogen 1.47 1.29, 1.67 <0.0001
Fibrinogen + Age 1.36 1.18, 1.57 <0.0001
Fibrinogen + Age + Race 1.30 1.13, 1.50 0.0004
Fibrinogen + Age + Race + Systolic Blood Pressure 1.29 1.12, 1.49 0.0008
Fibrinogen + Age + Race + Systolic Blood Pressure
+ Lipids*
1.35 1.17, 1.55 <0.0001
Fibrinogen + Age + Race + Systolic Blood Pressure
+ Other potential risk factors†
1.36 1.18, 1.57 0.0001
*
Lipids included log-transformed triglycerides, high density lipoprotein cholesterol, and low density lipoprotein cholesterol.
†
Lipids, pack-year categories, body-mass index, education, alcohol consumption, and diabetes status.
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